Logotipo do repositório

Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model

dc.contributor.authorGrandini, Núbia Alves
dc.contributor.authorCosta, Mariane Róvero
dc.contributor.authorGregolin, Cristina Schmitt
dc.contributor.authorSiqueira, Juliana Silva
dc.contributor.authorVieira, Taynara Aparecida
dc.contributor.authorTogneri Ferron, Artur Junio
dc.contributor.authorFrancisqueti-Ferron, Fabiane Valentini
dc.contributor.authorRomualdo, Guilherme Ribeiro
dc.contributor.authorFerreira, Ana Lucia dos Anjos
dc.contributor.authorAldini, Giancarlo
dc.contributor.authorCamacho, Camila Renata Correa
dc.contributor.authorMoreto, Fernando
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)pt
dc.date.accessioned2026-09-10T19:50:02Z
dc.date.issued2023-12-24
dc.description.abstractConsumption of diets high in sugar and fat is related to the development of Metabolic dysfunction-associated steatotic liver disease (MASLD). Carnosine (CAR) is a dipeptide with antioxidant and anti-inflammatory action and has been studied for treating diseases. This work aimed to evaluate the effects of CAR on diet-induced MASLD in rats. Male Wistar rats were distributed into 2 groups (17 weeks): normocaloric (Co, n = 12), and hypercaloric diet rich in lipids and simple carbohydrates (MASLD, n = 12). After, the animals were redistributed to begin the treatment with CAR (4 weeks): Co (n = 6), Co + CAR (n = 6), MASLD (n = 6), and MASLD + CAR (n = 6), administered intraperitoneally (250 mg/kg). Evaluations included nutritional, hormonal and metabolic parameters; hepatic steatosis, inflammatory and oxidative markers. MASLD group had a higher adiposity index, systolic blood pressure, glucose, plasma and liver triglycerides and cholesterol, insulin, hepatic steatosis, oxidative markers, and lower PPAR-α (Peroxisome Proliferator-activated receptor α), compared to the Co. CAR attenuated plasma and hepatic triglyceride and cholesterol levels, hepatic steatosis, CD68<sup>+</sup> macrophages, and hepatic oxidative markers, in addition to increasing HDL cholesterol levels and PPAR-α, compared to the untreated MASLD group. CAR acts in importants pathophysiological processes of MASLD and may be a therapeutic compound to control the disease.
dc.description.affiliationSão Paulo State University (UNESP), Medical School, 18618687, Botucatu, Brazil. Electronic address: nubia.grandini@unesp.br.
dc.description.affiliationSão Paulo State University (UNESP), Medical School, 18618687, Botucatu, Brazil.
dc.description.affiliationIntegrated Colleges of Bauru (FIB), 17056-100, Brazil.
dc.description.affiliationDepartment of Pharmaceutical Sciences, University of Milan, 20133, Milan, Italy.
dc.description.affiliationUnespSão Paulo State University (UNESP), Medical School, 18618687, Botucatu, Brazil. Electronic address: nubia.grandini@unesp.br.
dc.description.affiliationUnespSão Paulo State University (UNESP), Medical School, 18618687, Botucatu, Brazil.
dc.identifierhttps://app.dimensions.ai/details/publication/pub.1167317804
dc.identifier.dimensionspub.1167317804
dc.identifier.doi10.1016/j.mce.2023.112138
dc.identifier.issn0303-7207
dc.identifier.issn1872-8057
dc.identifier.lattes4212573248044200
dc.identifier.orcid0000-0002-1696-4993
dc.identifier.orcid0000-0002-2004-3097
dc.identifier.orcid0000-0002-9175-9076
dc.identifier.orcid0000-0003-3172-2199
dc.identifier.orcid0000-0002-5312-0060
dc.identifier.orcid0000-0003-2910-4308
dc.identifier.orcid0000-0001-5320-8380
dc.identifier.orcid0000-0002-2355-6744
dc.identifier.orcid0000-0001-8493-5329
dc.identifier.orcid0000-0002-6915-4230
dc.identifier.orcid0000-0002-4028-0014
dc.identifier.pmid38147954
dc.identifier.urihttps://hdl.handle.net/11449/331635
dc.publisherElsevier
dc.relation.ispartofMolecular and Cellular Endocrinology; v. 582; p. 112138
dc.rights.accessRightsAcesso abertopt
dc.rights.sourceRightsoa_all
dc.rights.sourceRightsgreen
dc.sourceDimensions
dc.titleEffects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model
dc.typeArtigopt
dspace.entity.typePublication
relation.isAuthorOfPublication6ce24157-2253-483c-8e3c-22781f761c0c
relation.isAuthorOfPublication7913e795-75ef-4e6b-9ef5-40ff18c6b8ee
relation.isAuthorOfPublicationcbbc16a9-ccd0-4c78-97ec-4712742d50fe
relation.isAuthorOfPublicatione2bfb9e9-3541-4dc3-a1b1-86d587a7d519
relation.isAuthorOfPublicationa76c8ee4-dc21-4352-9ca0-a6bc4a852957
relation.isAuthorOfPublication4edd6706-980d-481e-974c-79ba57623c06
relation.isAuthorOfPublication4c8634bf-7551-46b7-a065-e4ff61a4b6a8
relation.isAuthorOfPublication.latestForDiscovery6ce24157-2253-483c-8e3c-22781f761c0c
relation.isAuthorOfPublication.latestForDiscovery7913e795-75ef-4e6b-9ef5-40ff18c6b8ee
relation.isAuthorOfPublication.latestForDiscoverycbbc16a9-ccd0-4c78-97ec-4712742d50fe
relation.isAuthorOfPublication.latestForDiscoverye2bfb9e9-3541-4dc3-a1b1-86d587a7d519
relation.isAuthorOfPublication.latestForDiscoverya76c8ee4-dc21-4352-9ca0-a6bc4a852957
relation.isAuthorOfPublication.latestForDiscovery4edd6706-980d-481e-974c-79ba57623c06
relation.isAuthorOfPublication.latestForDiscovery4c8634bf-7551-46b7-a065-e4ff61a4b6a8
relation.isOrgUnitOfPublicationa3cdb24b-db92-40d9-b3af-2eacecf9f2ba
relation.isOrgUnitOfPublication.latestForDiscoverya3cdb24b-db92-40d9-b3af-2eacecf9f2ba
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
1-s2.0-S0303720723002897-main.pdf
Tamanho:
5,47 MB
Formato:
Adobe Portable Document Format